Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Heptares Therapeutics
Heptares Therapeutics
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection
The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
New FAIRY viral assay could 'revolutionise' the response to future pandemics
The assay, which can detect the infectiousness of a virus in a matter of minutes, offers a quicker and cheaper alternative to the standard cell culture approach
New advice from BOLA and Labtex on cleaning and handling of PTFE products after use
The companies share: "Abrasive scouring agents may result in a milkiness of the vessels made of PFA and FEP. You may use all neutral detergents (pH 7). For higher contamination...
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Media
Heptares enters drug collaboration with Imperial
Heptares, the wholly-owned subsidiary of Sosei Group Corporation, has entered a new drug research and development collaboration with Imperial College London
Manufacturing
Heptares founder Richard Henderson receives Nobel Prize in Chemistry 2017
Research & Development
Heptares enters research and drug discovery collaboration
Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, launched a new research collaboration under its ORBIT initiative with Juntendo University in Tokyo, Japan
Research & Development
New programme focused on GPCR target implicated in brain cancer
Heptares Therapeutics announced the launch of a new research collaboration under its ORBIT initiative with New York University School of Medicine
Research & Development
Heptares plans relocation to Cambridge, UK
Heptares is planning to create a state of the art research and development facility on Granta Park to support its growth strategy
Research & Development
John Daly Lecture Award for Heptares’ co-founder
Heptares’ co-founder and Chief Scientific Officer, Fiona Marshall, receives 2017 John Daly Lecture Award in recognition of her outstanding contribution to GPCR drug discovery
Research & Development
New insights to advance drug discovery in pain, cancer and inflammation
Heptares collaboration with AstraZeneca yields novel mechanisms of action highlighted from resolved structures of PAR2 bound to antagonist molecules
Subscribe now